465.67  -1.39 (-0.3%)		11-13 16:00
Open: 467.53 High: 468 Volume: 1,477,785		Pre. Close: 467.06 Low: 462.22 Market Cap: 251,886(M)

Short term
Mid term
Targets	6-month :	565.3	1-year :	660.27
Resists	First :	483.98	Second :	565.3
Pivot price	461.88
Supports	First :	438.9	Second :	411.04
MAs	MA(5) :	466.26	MA(20) :	455.85
	MA(100) :	409.44	MA(250) :	368.01
MACD	MACD :	11.7	Signal :	12.4
%K %D	K(14,3) :	62.4	D(3) :	63.7
RSI	RSI(14): 61.7
52-week	High :	483.98	Low :	306.12

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ AMGN ] has closed below upper band by 38.5%. Bollinger Bands are 36% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	468.56 - 471.49	471.49 - 473.56
Low:	455.18 - 458.88	458.88 - 461.49
Close:	460.81 - 466.23	466.23 - 470.05

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Sun, 15 Nov 2026
Read This Before Considering Amgen Inc. (NASDAQ:AMGN) For Its Upcoming US$2.52 Dividend - Simply Wall St

Fri, 13 Nov 2026
Here’s How Much You Would Have Made Owning Amgen Stock In The Last 15 Years - Benzinga

Thu, 12 Nov 2026
Amgen Inc. (AMGN) Stock Forecasts - Yahoo Finance

Thu, 12 Nov 2026
Why Did Amgen (NASDAQ:AMGN) Slip After a Beat-and-Raise Quarter? - Kalkine Media

Wed, 11 Nov 2026
AMGEN ANNOUNCES POSITIVE PHASE 3 RESULTS FOR DAZODALIBEP IN SJÖGREN'S DISEASE - Quantisnow

Mon, 09 Nov 2026
Amgen (AMGN) Highlights Cost-Effectiveness of Repatha in New Car - GuruFocus

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Shares Out	541 (M)
Shares Float	539 (M)
Held by Insiders	0.2 (%)
Held by Institutions	85.1 (%)
Shares Short	13,380 (K)
Shares Short P.Month	14,060 (K)

EPS	17.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	26.53
Profit Margin	24.1 %
Operating Margin	35.7 %
Return on Assets (ttm)	8.9 %
Return on Equity (ttm)	78.3 %
Qtrly Rev. Growth	8.5 %
Gross Profit (p.s.)	52.11
Sales Per Share	71.91
EBITDA (p.s.)	32.59
Qtrly Earnings Growth	19.3 %
Operating Cash Flow	12,040 (M)
Levered Free Cash Flow	7,380 (M)

PE Ratio	26.99
PEG Ratio	2.7
Price to Book value	17.55
Price to Sales	6.47
Price to Cash Flow	20.92

Dividend	2.51
Forward Dividend	0
Dividend Yield	0.5%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.